Related Experiment Video

Updated: Mar 20, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K

Novel agents in second-line therapy for EGFR wild-type Advanced Non-Small-Cell Lung Cancer

L El Amarti1,2, I Elghissassi1,2, M Layachi1,2

  • 1Department of Medical Oncology, National Institute of Oncology, Rabat, Morocco.

The Gulf Journal of Oncology
|June 3, 2016
PubMed

Insights

For advanced non-small cell lung cancer (NSCLC) with wild-type EGFR, second-line therapies like ramucirumab, vandetanib, nivolumab, and pembrolizumab offer new options after initial treatment failure. This review updates clinicians on these choices for improved patient outcomes.

Area of Science:

  • Oncology
  • Pulmonology
  • Pharmacology

Background:

  • Lung cancer is a leading cause of cancer mortality, often diagnosed at advanced stages.
  • Most patients with non-small cell lung cancer (NSCLC) require second-line therapy after first-line treatment failure.
  • EGFR wild-type NSCLC lacks targeted therapy options, frequently leading to cytotoxic chemotherapy use.

Purpose of the Study:

  • To review current second-line treatment options for advanced EGFR wild-type NSCLC patients.
  • To discuss considerations for selecting appropriate second-line agents.
  • To provide an update on emerging therapies and patient selection strategies.

Main Methods:

  • Literature review of clinical trials and guidelines for second-line therapy in advanced NSCLC.
  • Analysis of efficacy and safety data for key agents including ramucirumab, vandetanib, nivolumab, and pembrolizumab.
  • Discussion of patient stratification based on histology, molecular markers, and immune targets.

Main Results:

  • Ramucirumab, vandetanib, nivolumab, and pembrolizumab represent key second-line treatment options for EGFR wild-type NSCLC.
  • Advances in understanding lung cancer biology facilitate better patient selection for targeted and immunotherapies.
  • These agents offer alternatives to traditional cytotoxic chemotherapy, potentially improving outcomes.

Conclusions:

  • Second-line treatment for advanced EGFR wild-type NSCLC has evolved beyond cytotoxic chemotherapy.
  • Personalized treatment selection based on molecular and immunological profiles is crucial.
  • Further research and clinical experience will refine optimal sequencing and combination strategies.
Keywords:
EGFR wild typeNintedanibNivolumabPembrolizumab.Ramucirumabnon-small-cell lung cancersecondline treatment

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
537
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K